Instigo-D Tablet is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, indicated for the management of gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and enhances esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The synergistic action of these agents provides effective symptomatic relief in gastroesophageal reflux disease (GERD), peptic ulcer disease, and functional dyspepsia. Instigo-D is typically administered orally, once daily before meals, with dosage adjustments based on clinical response and patient tolerance. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Common adverse effects may include headache, dry mouth, and abdominal discomfort. This combination therapy should be used under medical supervision, ensuring appropriate evaluation of underlying causes and monitoring for potential drug interactions.